UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, D.C. 20549

__________________________

FORM 8-K

CURRENT REPORT

~~Pursuant~~PURSUANT toTO ~~Section~~SECTION 13 orOR 15(d) ofOF

~~the~~THE ~~Securities~~SECURITIES ~~Exchange~~EXCHANGE ~~Act~~ACT ofOF 1934

Date of Report (Date of earliest event reported): June ~~April 18~~19, 2017

IMMUCOR, INC.

(Exact ~~name~~Name of ~~registrant~~Registrant as ~~specified~~Specified in its ~~charter~~Charter)

Georgia	~~0-14820~~	220-~~2408354~~14820	22-2408354
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or Other Jurisdiction of		(Commission File Number)	(IRS Employer Identification
Incorporation)			Number)

3130 Gateway Drive, Norcross, Georgia	30071
3130 Gateway Drive
(Address of principal executive offices)	(Zip Code)
Norcross, Georgia		30071
(Address of Principal Executive Office)		(Zip Code)

Registrant'’s telephone number, including area code: (770) 441-2051

~~Not Applicable~~N/A

(Former ~~name~~Name or ~~former~~Former ~~address~~Address, if Changed Since Last Report)

Check the appropriate box below if ~~changed~~the ~~since~~Form ~~last~~8-K ~~report.)~~filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

~~Check~~☐ Written ~~the~~communications ~~appropriate~~pursuant ~~box below if the Form 8-K filing is intended~~ to ~~simultaneously~~Rule ~~satisfy~~425 ~~the filing obligation of the registrant~~ under ~~any of~~ the ~~following~~Securities ~~provisions~~Act (~~see~~17 ~~General~~CFR ~~Instruction A~~230.~~2. below~~425):

[☐ Soliciting ]material ~~Written communications~~ pursuant to Rule ~~425~~14a-12 under the ~~Securities~~Exchange Act (17 CFR ~~230~~240.~~425~~14a-12)

[☐ Pre-commencement ]communications ~~Soliciting material~~ pursuant to Rule ~~14a~~14d-122(b) under the Exchange Act (17 CFR 240.~~14a~~14d-122(b))

~~[ ]~~ ☐ Pre-commencement communications pursuant to Rule ~~14d~~13e-24(bc) under the Exchange Act (17 CFR 240.~~14d~~13e-24(bc))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 28.0501 ~~Costs~~Other ~~Associated with Exit or Disposal Activities~~Events.

On ~~April~~June 1819, 2017, Immucor, Inc. (~~the~~ “~~Company~~Immucor”) ~~committed~~issued to a ~~cost~~press ~~reduction~~release ~~exercise.~~announcing ~~The~~the ~~Company~~commencement ~~has invested heavily across all facets~~ of ~~its~~an ~~business~~offer ~~since~~to ~~its~~eligible ~~acquisition~~holders byto ~~TPG~~exchange ~~Capital~~any ~~in August 2011. These investments have included people, systems, processes~~ and ~~acquisitions,~~all ~~resulted in an increase~~ of ~~more~~Immucor’s ~~than~~outstanding ~~$60~~11.125% ~~million~~Senior inNotes ~~our~~due ~~cost~~2019 ~~base and added nearly 400 people to~~ (the ~~organization.~~“Old ~~The~~Notes”) ~~Company~~for ~~has undertaken~~ a ~~review~~new series of ~~its~~11.125% ~~cost~~Senior ~~structure~~Notes ~~and~~due ~~has~~2022 ~~taken~~(the ~~steps~~“New ~~to become more efficient and streamline our organization~~Notes”).

AsThe ~~part~~information ofcontained in this ~~exercise,~~report ~~the~~on ~~Company~~Form ~~expects~~8-K todoes ~~generate~~not ~~approximately~~constitute ~~$15~~an ~~million~~offer into ~~annual~~purchase, ~~cost~~the ~~savings~~solicitation ~~beginning~~of inan ~~fiscal~~offer ~~year~~to ~~2018~~purchase, asor a ~~result~~solicitation of ~~reductions~~tenders. inThe ~~both~~New ~~headcount~~Notes have not been and ~~discretionary~~will ~~spending.~~not Inbe ~~connection~~registered ~~with~~under ~~this~~the ~~cost~~Securities ~~reduction~~Act ~~exercise~~or any state securities laws, ~~the~~and, ~~Company~~unless ~~expects~~so toregistered, ~~incur~~may ~~approximately~~not $3be ~~million~~offered ~~during~~or sold in the ~~fourth~~United ~~quarter~~States ofor ~~fiscal~~to ~~year~~any ~~2017~~U.S. persons except pursuant to an exemption from, or in ~~one-time~~a ~~expenses~~transaction subject to, ~~primarily~~the ~~for~~registration ~~severance~~ requirements of the Securities Act and ~~other~~any ~~employee-related~~applicable ~~termination~~state ~~costs~~securities laws.

~~Forward-Looking~~Item 9.01. Financial Statements and Exhibits

~~Certain~~(d) statements herein, including the expected benefits from the Company’s cost reduction exercise, are “forward-looking statements” based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but any forward-looking statements are subject to various risks and uncertainties and there can be no assurance that the Company will realize its expectations or that its beliefs will prove correct. Actual results of operations may differ materially from current expectations. Exhibits

Important factors that could cause the Company’s actual results to differ materially from forward-looking statements are set forth in the section entitled “Risk Factors” and elsewhere in the Company’s Annual Report on Form 10-K and in all filings with the SEC made subsequent to the filing of the Form 10-K. The Company does not undertake to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Exhibit	Exhibit Name

99.1	Press Release, dated June 19, 2017, entitled “Immucor, Inc. Announces Exchange Offer”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMMUCOR, INC.
Date: April 19, 2017	By:	/s/ Dominique Petitgenet
Date: June 19, 2017	By:	/s/ Dominique Petitgenet
		Dominique Petitgenet
		Name: Dominique Petitgenet
		Vice President and Chief Financial Officer
		Title: Vice President and Chief Financial Officer

Filing Compare · IMMUCOR INC